Sana Biotechnology, Inc.
NASDAQSana Biotechnology enters the second half of 2026 with a tightening contradiction: short sellers are quietly adding exposure while options traders have turned more bullish than at almost any point in the past year. The short-side rebuilding is the more concrete story. Short interest has climbed to 15.9% of the free float — up roughly 10% over the past month and accelerating in the…
Snapshot as of 10 Aug 2026
Sana Biotechnology enters the second half of 2026 with a tightening contradiction: short sellers are quietly adding exposure while options traders have turned more bullish than at almost any point in the past year. The…
SANA enters its May 14 earnings report carrying one of the most crowded short books in its sector — and the bears have not blinked. Short interest runs at 14.5% of the free float, a level that places the stock in the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SANA — free to start on ORTEX.
Sign up for free →Open SANA on ORTEX